曲妥珠单抗与帕妥珠单抗双靶治疗在人表皮生长因子受体-2阳性乳腺癌新辅助治疗中的应用效果  

Effect of Trastuzumab and Pertuzumab Double Target Therapy in Neoadjuvant Therapy of Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer

作　　者：叶泽霖 郑金珠 冯杰鑫 吴雄 YE Zelin;ZHENG Jinzhu;FENG Jiexin;WU Xiong(Zhangzhou Hospital Affiliated to Fujian Medical University,Zhangzhou 363000,China)

机构地区：[1]福建医科大学附属漳州市医院,漳州363000

出　　处：《中国医药指南》2024年第1期100-103,共4页Guide of China Medicine

摘　　要：目的探讨并分析曲妥珠单抗联合帕妥珠单抗治疗方案在人表皮生长因子受体-2阳性乳腺癌新辅助治疗中的应用效果。方法选取2019年4月至2022年6月福建医科大学附属漳州市医院收治的52例人表皮生长因子受体-2阳性乳腺癌患者展开研究,遵循随机数字表法分组原则,将其分成观察组与对照组,各26例,予以对照组紫杉醇、卡铂和曲妥珠单抗疗法,予以观察组曲妥珠单抗与帕妥珠单抗双靶治疗,将两组治疗效果进行比较。结果观察组治疗有效率88.46%高于对照组65.39%(P<0.05)。观察组术后病理缓解率96.15%高于对照组65.38%(P<0.05);且观察组病理完全缓解率高达50.00%,高于对照组26.92%(P<0.05)。治疗前,对比两组患者生活质量各维度的评分差异无统计学意义(P>0.05);治疗后,两组生活质量各个维度评分均有所提高,其中观察组各维度的评分高于对照组(P<0.05)。观察组不良反应发生率26.92%与对照组不良反应发生率30.77%对比差异无统计学意义(P>0.05)。结论人表皮生长因子受体-2阳性乳腺癌中通过曲妥珠单抗与帕妥珠单抗双靶治疗的临床疗效显著,不仅能够有效提高病理缓解率,还有助于患者生活质量的提升,同时也不会增加不良反应,可以作为新辅助治疗中的新思路应用于临床。Objective To explore and analyze the effect of the combination of trastuzumab and patuzumab in the neoadjuvant treatment of human epidermal growth factor receptor 2 positive breast cancer.Methods 52 cases of human epidermal growth factor receptor-2 positive breast cancer patients admitted to our hospital from April 2019 to June 2022 were selected for research.They were divided into the observation group(n=26)and the control group(n=26)according to the principle of random number table grouping.The control group was treated with paclitaxel,carboplatin and trastuzumab,and the observation group was treated with dual target therapy of toluzumab and patuzumab.The therapeutic effects of the two groups were compared.Results The effective rate of the observation group was 88.46%,higher than the control group's 65.39%(P<0.05).The postoperative pathological remission rate of the observation group after treatment reached 96.15%,higher than the control group's 65.38%(P<0.05);The complete pathological remission rate in the observation group was as high as 50.00%,higher than the control group's 26.92%(P<0.05).Before treatment,there was no statistically significant difference in the scores of various dimensions of quality of life between the two groups of patients(P>0.05);After treatment,the scores of various dimensions of quality of life in both groups improved,but the scores of each dimension in the observation group were higher(P<0.05).The incidence of adverse reactions was 26.92%in the observation group and 30.77%in the control group,with no statistically significant difference between the groups(P>0.05).Conclusions In human epidermal growth factor receptor-2 positive breast cancer,the clinical efficacy of dual target therapy with trastuzumab and patuzumab is significant,which can not only effectively improve the pathological remission rate,but also help to improve the quality of life of patients,without increasing adverse reactions.It can be used as a new idea in new adjuvant therapy in clinical application.

关 键 词：曲妥珠单抗 帕妥珠单抗 双靶治疗 人表皮生长因子受体-2阳性乳腺癌 新辅助治疗 

分 类 号：R737.9[医药卫生—肿瘤]